Literature DB >> 22409864

Response of metastatic renal medullary carcinoma to carboplatinum and Paclitaxel chemotherapy.

Venu gopala reddy Gangireddy1, Georgia B Liles, Gilberto D Sostre, Teresa Coleman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22409864     DOI： 10.1016/j.clgc.2012.01.003

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  4 in total

Review 1.  Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory.

Authors:  Nigel S Key; Philippe Connes; Vimal K Derebail
Journal:  Br J Haematol       Date:  2015-03-07       Impact factor: 6.998

2.  Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.

Authors:  Jacob S Lipkin; Syed M Rizvi; Zoran Gatalica; Nabeel E Sarwani; Sheldon L Holder; Mathew Kaag; Joseph J Drabick; Monika Joshi
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

3.  Renal Medullary Carcinoma Masquerading as Bilateral Breast Carcinoma Category: Case Report.

Authors:  Madhurima Anne; Daniel Sammartino; Shweta Chaudhary; Tawfiqul Bhuiya; Bhoomi Mehrotra
Journal:  World J Oncol       Date:  2013-07-15

4.  Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study.

Authors:  Zoé Guillaume; Emeline Colomba; Jonathan Thouvenin; Carolina Saldana; Luca Campedel; Clément Dumont; Brigitte Laguerre; Denis Maillet; Cécile Vicier; Frédéric Rolland; Delphine Borchiellini; Philippe Barthelemy; Laurence Albiges; Edouard Auclin; Matthieu Roulleaux Dugage; Stéphane Oudard; Constance Thibault
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.